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AbstrAct
Introduction Respiratory viruses causing lower 
respiratory tract infections (LRTIs) are a major cause of 
hospital admissions in children. Since the course of these 
infections is unpredictable with potential fast deterioration 
into respiratory failure, infants are easily admitted to the 
hospital for observation. The aim of this study was to 
examine whether systemic inflammatory markers can 
be used to predict severity of disease in children with 
respiratory viral infections.
Methods Blood and nasopharyngeal washings from 
children <3 years of age with viral LRTI attending a 
hospital were collected within 24 hours (acute) and after 
4–6 weeks (recovery). Patients were assigned to a mild 
(observation only), moderate (supplemental oxygen 
and/or nasogastric feeding) or severe (mechanical 
ventilation) group. Linear regression analysis was used 
to design a prediction rule using plasma levels of C 
reactive protein (CRP), serum amyloid A (SAA),  
pentraxin 3 (PTX3), serum amyloid P component and 
properdin. This rule was tested in a validation  
cohort.
Results One hundred and four children (52% male) 
were included. A combination of CRP, SAA, PTX3 and 
properdin was a better indicator of severe disease 
compared with any of the individual makers and age 
(69% sensitivity (95% CI 50 to 83), 90% specificity 
(95% CI 80 to 96)). Validation in 141 patients resulted 
in 71% sensitivity (95% CI 53 to 85), 87% specificity 
(95% CI 79 to 92), negative predictive value of 64% 
(95% CI 47 to 78) and positive predictive value of 90% 
(95% CI 82 to 95). The prediction rule was not able to 
identify patients with a mild course of disease.
Conclusion A combination of CRP, SAA, PTX3 and 
properdin was able to identify children with a severe 
course of viral LRTI disease, even in children under 
2 months of age. To assess the true impact on clinical 
management, these results should be validated in a 
prospective randomised control study.
IntroductIon
Acute lower respiratory tract infections 
(LRTIs) annually result in hospitalisation of 
0.9%–1.36% of a birth cohort.1 2 Eventually, 
6% to 15% of these patients are admitted to 
the intensive care unit (ICU).1 3 Young age 
and prematurity are the most important risk 
factors for severe diseases. This is reflected 
by the fact that over 50% of the children 
admitted to the ICU have no other risk factors 
besides young age.1 4 5
Infants under 2 to 3 months of age are 
easily admitted to the hospital due to a poten-
tially rapid progression of disease. More 
than one-third of all patients hospitalised 
with acute respiratory viral infections do not 
receive supportive care.5 However, 5% of the 
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Strengths and limitations of this study
 ► Two independent cohorts of young infants were 
used to identify and validate plasma biomarkers 
to assess severity of disease in children with viral 
lower respiratory tract infection (LRTI).
 ► Linear regression modelling was used to combine 
markers to optimise predictive value.
 ► Performance of our model was tested and validated 
in children under 2 months of age, the group that is 
clinically most relevant for severedisease.
 ► Other known inflammatory markers, such as 
procalcitonin, were not included and could have 
increased the clinical performance of test.
 ► This observational cohort study was performed 
during hospital admission of children with clinical 
signs of viral LRTI, validation in earlier stages of 
disease at GP office or ER would be more informative 
regarding clinical application.
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patients discharged from the emergency room require 
readmission at a later stage of the infection.6 Therefore, 
there is a need for biomarkers that can predict the course 
of disease in infants with viral respiratory tract infections.
Currently, there are clinical prediction rules to 
predict safe discharge, length of hospitalisation and 
ICU admission for children with acute respiratory viral 
infections based on demographic criteria and clinical 
symptoms.4 5 7–11 Although these clinical prediction rules 
show the potential to improve clinical judgement, valida-
tion in other cohorts is often lacking or implementation 
in daily practice is difficult due to subjective criteria.8 9 
Moreover, children under 2 months of age were either 
excluded or the studies were designed in such a way that 
all patients in this age group were automatically admitted 
to the hospital. A more objective, reproducible and sensi-
tive prediction of disease severity for all age groups may 
be achieved by using biochemical and haematological 
markers.12–16
Therefore, plasma proteins that were not yet extensively 
studied in the context of viral LRTI were identified from 
the literature. Pentraxin 3 (PTX3) has been described 
as an early sensitive and specific marker for bacterial 
pneumonia in bronchoalveolar lavages of mechanically 
ventilated adults, and as a severity marker of menin-
gococcal disease in children.17 18 In 2016, a study was 
published that showed that PTX3 levels are also a marker 
for LRTI in children and is more sensitive than C reac-
tive protein (CRP), which is frequently used in clinical 
care.19 No correlation between CRP levels and severity 
of viral disease has been described. When CRP levels 
are very high, they indicate bacterial infection; however, 
often, CRP is moderately increased and then CRP is not 
able to differentiate between viral or bacterial aetiology 
of infection.20–23 Serum amyloid A (SAA) appears to be 
more sensitive than CRP for the detection of bacterial 
infections in neonates, although it is not used in daily 
practice.24 The SAA/CRP ratio can be used as a marker 
for severe disease in children with bacterial infections.25 
Nakayama et al have shown that SAA levels increase in 
children with different viral infections, including viral 
LRTI. However, an association with disease severity was 
not established.26 Serum amyloid P component (SAP) 
can activate the classical complement pathway and inter-
acts with mannan-binding lectin. SAP is part of a family of 
pattern recognition receptors, the pentraxin family. CRP 
and PTX3 belong to the same family. SAP is involved in 
inflammation and used as a marker for atherosclerosis 
and autoimmune disease.27 Skinner et al have shown that 
SAP levels were not increased during bacterial pneu-
monia, suggesting a limited potential as biomarker in 
infectious disease.28 No studies were found that assessed 
the role of SAP during viral infections; since its family 
members show potential as biomarker in viral disease, we 
decided to include SAP in this study.
Properdin (CFP) is a positive regulator of the alter-
native pathway of the complement system and it is a 
pattern recognition molecule that can bind to apoptotic/
necrotic cells or microbial pathogens (including viruses) 
to facilitate phagocytosis and clearance.29 30 Recently, the 
immunological potential of CFP is gaining attention. In 
the context of kidney disease, the role of properdin is 
becoming more apparent; moreover it has been demon-
strated that properdin can be activated via neutrophil 
extracellular traps. These traps are also present during 
viral LRTI and studied in the context of severe RSV infec-
tions.31 32 Familial deficiencies in CFP are known and are 
associated with susceptibility to meningococcal infec-
tions.33 34 However, an increased susceptibility to viral 
infections has never been published.
In this study, we tested the aforementioned plasma 
proteins for their correlation with severity of viral LRTIs 
in children.
MaterIals and Methods
study design
Children younger than 3 years of age were eligible 
for inclusion in this prospective cohort study if they 
attended one of the two hospitals in Nijmegen from 
September until May with symptoms of an acute viral 
LRTI. Symptoms included signs of increased respiratory 
effort (eg, tachypnoea and/or use of accessory respira-
tory muscles or retractions) and/or expiratory wheezing 
and/or crackles on auscultation and/or apnoea. Patients 
with congenital or acquired immune deficiencies, 
immunosuppressive medication (including >24 hours 
of corticosteroids) or severe psychomotor retardation 
were excluded. Eligible patients were identified by their 
physician who diagnosed a viral LRTI and notified the 
study team. In both hospitals, it was not common prac-
tice to perform laboratory, rontgen or viral diagnostics 
at time of presentation; therefore, inclusions were 
made based on clinical appearance. When informed 
consent of both parents was obtained within 24 hours of 
admission, patients were included in the study. Data on 
clinical parameters, course of disease, medical history 
and demographics were retrieved from medical records 
and questionnaires retrieved at inclusion and after 4–6 
weeks. Participation in this study did not influence 
medical care, and study results from individual patients 
were not shared with the medical team. Retrospectively, 
after discharge patients were allocated into three groups: 
mild, send home or only clinical observation; moderate, 
patients with need for supplemental oxygen and/or 
nasogastric feeding; and severe, patients with mechanical 
ventilation. Supplemental oxygen was started according 
to the protocols from the clinical wards in patients with 
an oxygen saturation of ≤92% for at least 10 min after 
use of decongestives. Results were evaluated in a training 
cohort (n=104, 2010–2012) and subsequently tested 
in a larger historical validation cohort with the same 
inclusion and exclusion criteria (n=141, 2006–2009). 
The study was approved by the Committee on Research 
involving Human Subjects.
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Table 1 Patient characteristics
Total
n=104 (%) Mild n=20 (%) Moderate n=52 (%) Severe n=32 (%) p Value
Gender (male) 54 (52%) 12 (60%) 24 (46%) 18 (56%) NS
Age (days) 92 (38.2–289.8) 129 (63.0–368.3) 165.0 (66.0–422.0) 37.5 (22.0–86.5) <0.001*
Prematurity (<35 weeks) 5 (5%) 1 (5%) 3 (6%) 1 (3%) NS
Onset symptoms (days) 3.0 (2.0–4.8) 2.5 (1.3–3.8) 3.0 (2.0–5.0) 4.0 (2.0–4.8) NS
Duration admission (days) 6.5 (3.3–10.8) 2.0 (2.0–3.0) 6.0 (4.0–8.0) 11.0 (9.3–13.8) <0.001**
RSV infection 68 (65%) 8 (40%) 38 (73%) 23 (72%) <0.05***
% mono-infection RSV 39 (57%) 3 (37.5%) 20 (53%) 16 (70%) <0.001
Values are given in numbers (percentages) or medians (25th–75th percentiles). NS not signifficant.
 *Mild versus severe p=0.001, moderate versus severe p<0.0001.
**Mild versus moderate/severe p<0.0001, moderate versus severe p<0.0001
***Mild versus moderate/severe (p<0.05).
Material collection
After informed consent, blood and a nasopharyngeal 
wash were collected within 24 hours (acute), and after 
4–6 weeks (recovery). A venous blood sample (3 mL) 
was collected in sodium heparin tubes and immediately 
transported to the laboratory. Plasma (and cell fractions) 
were obtained after density centrifugation (Lymph-
oprep, Axis Shield, Norway) and stored at −80°C. After 
instilling 0.5 mL of saline into one of the nostrils, a cath-
eter was introduced into the nasopharynx to aspirate 
nasopharyngeal fluid. Samples were instantly put on 
ice, transported to the laboratory and stored at −80°C. 
Multiplex reverse transcription-PCR was performed on 
the nasal wash to confirm viral aetiology of disease, as 
previously described.35 This way, viral aetiology of disease 
was established for this study; however, this information 
was not available during treatment of the patient. The 
assay was designed to detect 15 viruses: influenza virus 
types A and B, coronavirus 229E and OC43, bocavirus, 
enterovirus, adenovirus, parechovirus, PIV types 1–4, 
metapneumovirus, rhinovirus and RSV.
elIsa
Levels of SAA, SAP, PTX3, CFP and CRP were deter-
mined in twofold diluted plasma by ELISA following the 
manufacturer’s instructions (Hycult Biotech, Uden, The 
Netherlands, catalogue numbers HK333, HK331, HK347, 
HK334 and HK358, respectively).
statistics
Data are expressed as percentages for categorical vari-
ables and as mean and SEM or median and IQR for 
the non-parametric continuous variables. Kruskal-Wallis 
tests were performed on continuous variables, followed 
by Mann-Whitney U test to further analyse differences. 
For categorical data, χ2 testing was used. Paired data 
were tested with the Wilcoxon signed-rank test. Correla-
tions were calculated using Spearman’s rho. The optimal 
predictive combination of proteins was selected using the 
M5 method linear regression, which removes classifiers 
with the smallest standardised coefficient one-by-one 
until no decrease in error estimate is observed. The 
outcome of the obtained rule was analysed for its receiver 
operating characteristics (ROCs). Cut-off values were 
determined for both mild and severe disease. These 
cut-offs were subsequently validated in a second cohort. 
A two-sided p value of <0.05 was considered statistically 
significant. A subanalysis was performed in children 
under 2 months of age, since this group is often excluded 
in other studies that describe prediction rules and age 
is an important factor in disease severity. Statistical tests 
were performed by SPSS for Windows (Release 19, SPSS) 
and Waikato Environment for Knowledge Analysis was 
used to perform linear regression.36
results
Patient characteristics
The training cohort consisted of 104 children (overall 
inclusion percentage 58%, off all patients/asked who 
were contacted informed consent was given in 77%, see 
supplemental flowchart) (table 1). Children with severe 
disease were significantly younger and had more often 
siblings than patients in the mild and moderate groups. 
The amount of children below 2 months of age is 5, 12 
and 21 in the mild, moderate and severe group, respec-
tively. Duration of hospitalisation significantly increased 
towards more severe disease. Two per cent of the patients 
were not hospitalised (2/104), whereas 17% of the hospi-
talised patients had only mild disease. RSV was detected in 
the majority of patients (65%), in 43% viral coinfections 
were present. The highest proportion of RSV mono-infec-
tions was seen in children with a severe course of disease 
(p<0.001), as was previously published by our group.35
Markers for infection and disease severity
Plasma levels of CRP, SAP, SAA and PTX3 increased signifi-
cantly during disease compared with levels in recovery 
samples, whereas CFP levels did not differ between these 
two time points (figure 1A–E). When the acute disease 
group was subdivided into three severity classes, plasma 
levels of CRP during severe disease were significantly 
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Figure 1 Comparison of plasma protein levels in children with acute respiratory viral infections with their paired recovery 
sample (n=51) taken 4–6 weeks after acute infection is shown for CFP (E), SAA (D), SAP (C), C reactive protein (CRP) (A) and 
PTX3 (B) (Wilcoxon matched-pairs signed-rank test). CRP, C reactive protein; PTX3, pentraxin 3; SAA, serum amyloid A; SAP, 
serum amyloid P component.
higher compared with patients with mild and moderate 
disease (figure 2A). Although there was a stepwise incline 
in plasma levels of PTX3, there were no significant differ-
ences (figure 2B). Plasma levels of SAP were also equal 
between the different disease severities (figure 2C). SAA 
plasma levels, however, were significantly higher during 
severe disease compared with mild disease (figure 2D). 
CFP plasma levels did not differ between mild and 
moderate disease. In contrast to the other markers, the 
CFP plasma levels dropped significantly in patients with 
severe disease (figure 2E).
Since disease severity can also be reflected by the dura-
tion of hospitalisation and the need for supplemental 
oxygen (as substitute for the need for hospitalisation), we 
tested whether they correlated with the plasma proteins. 
Both CRP and CFP correlated significantly with duration 
of hospitalisation (ρ=0.361, p≤0.001 and ρ=−0.22, p<0.05, 
respectively). However, PTX3, SAP and SAA levels did not. 
The need for supplemental oxygen was associated with 
higher levels of CRP and PTX3 (figure 2A–B), whereas 
the other markers showed no significant difference.
the influence of age and viral aetiology on protein levels
Children with severe disease are significantly younger 
(table 1); therefore, we checked whether age is a 
confounder for our protein levels. After stratification of 
the cohort per severity and age group (under and above 
2 months of age), protein levels were compared. After 
Bonferroni correction, no significant differences were 
found in the group under 2 months of age. Thus, although 
age is an important confounder for disease severity, the 
levels of the plasma markers are not only dependent on 
age and reflect disease severity.
RSV mono-infections are more frequently seen in the 
severe disease group (table 1). We tested whether patients 
with RSV mono-infections also had higher plasma levels 
compared with patients with the same disease severity 
without RSV mono-infections. We found that patients 
with RSV mono-infections had significantly higher SAA 
levels during severe disease (p<0.05). Levels of all other 
inflammatory markers were equal.
accuracy of the inflammatory markers to predict disease 
severity
After finding differences in plasma levels in patients with 
different disease severities, the diagnostic performance 
of the proteins was tested. First, the performance of the 
markers to indicate the need for hospitalisation (supple-
mental oxygen and/or nasogastric feeding) was assessed. 
Of 104 patients included for analysis, 27 did not receive 
supplemental oxygen: six of these patients belonged to 
the moderate group (table 1). The area under the curve 
(AUC) for the markers CRP and PTX3 was 0.63 and 0.64, 
respectively. The AUC for the other markers was 0.59 for 
SAA, 0.57 for SAP and 0.51 for CFP.
Second, the performance of markers to indicate the 
need for mechanical ventilation (severe disease) was 
assessed. Of 104 patients included for analysis, 32 were 
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Figure 2 Comparison of protein levels between patients with mild (n=21), moderate (n=51) and severe (n=32) disease and for 
patients with (n=77) and without (n=27) the need for supplemental oxygen are shown for C reactive protein (CRP) (A), PTX3 (B), 
SAP (C), SAA (D) and CFP (E) (Mann-Whitney U test). CRP, C reactive protein; PTX3, pentraxin 3; SAA, serum amyloid A; SAP, 
serum amyloid P component.
mechanically ventilated (table 1). The AUC of the 
markers that were associated with severe disease, CRP, 
SAA and CFP, was 0.73, 0.57 and 0.76, respectively. The 
AUC for the other markers was 0.56 for PTX3 and 0.53 
for SAP.
combining inflammatory markers increases performance
As reflected by the AUC, none of the single markers was 
considered sufficient to identify mild disease and thus aid 
in the decision to discharge a patient. Whereas the AUC 
of some markers for severe disease were slightly higher, 
none of them exceeded 0.8.
Therefore, linear regression modelling was used to 
analyse whether a combination of markers could increase 
the individual performance. The assumption was that 
distances between the three groups were equal. The linear 
regression resulted in the following model: (5.8xPTX-
3)+(1.15xCRP)–(4.1xCFP)–(0.93xSAA)+106.25. The 
AUC for this rule is 0.65 for mild disease (no need 
for supplemental oxygen) and 0.89 for severe disease 
(mechanical ventilation).
Based on the ROCs, a cut-off value for the identifica-
tion of mild disease was set at 93.50, which resulted in an 
AUC of 0.65 and sensitivity of 56% (95% CI 36 to 74), a 
specificity of 70% (95% CI 58 to 80), a positive predictive 
value (PPV) of 82% (95% CI 70 to 90) and a negative 
predictive value (NPV) of 39% (95% CI 24 to 56). In <2 
months old children, the AUC is 0.88 (sensitivity 87% 
(95% CI 69 to 96), specificity 71% (95% CI 30 to 95), 
PPV 93% (95% CI 76 to 99) and NPV 56% (95% CI 23 to 
85)), whereas in >2 months old patients, the AUC is 0.50 
(sensitivity 57% (95% CI 42 to 71), specificity 47% (95% 
CI 25 to 71), PPV 72% (95% CI 56 to 96) and NPV 31% 
(95% CI 16 to 51)).
The cut-off value for severe disease was set at 122 (sensi-
tivity 69% (95% CI 50 to 83), specificity 90% (95% CI 80 
to 96) with a PPV of 76% (95% CI 56 to 89) and an NPV 
of 87% (95% CI 76 to 93)) with an AUC of 0.88. In chil-
dren below 2 months of age, the AUC for severe disease 
increased to 0.90 (sensitivity 72% (95% CI 50 to 87), spec-
ificity 85% (95% CI 65 to 95), PPV 82% (95% CI 59 to 94) 
and NPV 77% (95% CI 57 to 89)). In older children, the 
AUC is 0.86 (sensitivity 55% (95% CI 25 to 82), specificity 
93% (95% CI 82 to 98), PPV 60% (95% CI 27 to 86) and 
NPV 91% (95% CI 80 to 97)).
Validation of prediction rules
A new cohort of 141 children was tested. Patient charac-
teristics of the original and validation cohort were similar 
with respect to their distribution of age, gender and 
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number of prematurely born infants (less than 35 weeks). 
The number of children below 2 months of age is 12, 23 
and 22, respectively. In contrast to the training cohort, 
the presence of siblings was not significantly different 
between the severity groups in the validation cohort 
(see online supplementary table 1 and supplementary 
figure 1).
need for hospitalisation
Validation of the prediction rule for mild disease, need 
for hospitalisation, resulted in 51% sensitivity (95% CI 37 
to 65) and 68% specificity (95% CI 58 to 78) (PPV 46% 
(95% CI 33 to 60) and NPV 72% (95% CI 62 to 81)). In 
children below 2 months of age, the rule performed better 
the AUC increased from 0.67 to 0.79 (sensitivity 55% 
(95% CI 33 to 75), specificity 81% (95% CI 70 to 89), 
PPV 46% (95% CI 27 to 66) and NPV 86% (95% CI 74 to 
92)). In children >2 months, the AUC decreased to 0.58 
(sensitivity 52% (95% CI 38 to 65), specificity 60% (95% 
CI50 to 70), PPV 42% (95% CI 30 to 55) and NPV 69% 
(95% CI 58 to 78)).
need for mechanical ventilation
When the prediction rule was applied to the validation set 
with a cut-off of 122, the sensitivity for severe disease was 
71% (95% CI 53 to 85) with 87% specificity (95% CI 79 to 
92), PPV and NPV were 64% (95% CI 47 to 78) and 90% 
(95% CI 82 to 95), respectively.
In children below 2 months of age, the AUC for severe 
disease is 0.87 (sensitivity 77% (95% CI 61 to 88), speci-
ficity 57%(95% CI 46 to 67), PPV 45% (95% CI 33 to 57), 
NPV 84% (95% CI 73 to 92)). In older children, the AUC 
remains 0.87 (sensitivity 58% (95% CI 37 to 77), speci-
ficity 90% (95% CI 83 to 94), PPV 52% (95% CI 32 to 71), 
NPV 92% (95% CI 85 to 96)).
Additional analyses were performed to assess the 
performance of logistic regression analysis; this was not 
possible for mild disease since all patients were allocated 
to the mild/severe group. For severe disease, the perfor-
mance of the rule was almost the same as compared with 
our linear regression model. The inclusion of age in the 
linear model resulted in a similar performance in the 
cohorts. In this rule, SAA was replaced with age.
dIscussIon
In this study, we show that plasma levels of CRP, PTX3, 
SAA and CFP correlate with disease severity in children 
with acute viral LRTI. Furthermore, we demonstrate that 
a combination of these markers significantly increased 
the performance of the individual proteins to identify 
patients with severe disease. The designed prediction 
rule has been validated in a larger independent patient 
cohort with similar characteristics, which resulted in a 
comparable performance. Moreover, the performance of 
the rule was best in patients under 2 months of age (<60.5 
days) in whom it is clinically difficult to predict the course 
of disease.
Interestingly, most of the inflammatory markers investi-
gated in this study have not been described in the context 
of viral LRTI or disease severity. The increase of CRP 
and SAA levels during viral infection was known and this 
was also the reason to include the proteins in our study. 
We were able to confirm the work of Huttunen et al that 
the ratio SAA/CRP is significantly decreased in patients 
with severe disease compared with patients with mild and 
moderate disease (data not shown).25 Moreover, CRP and 
SAA levels both correlated with severity of viral LRTIs 
and CRP was also correlated with length of hospitalisa-
tion. To the best of our knowledge, these findings have 
not been described before. The increase in PTX3 levels 
during more severe disease and a correlation with need 
for supplemental oxygen show the potential of PTX3 as 
biomarker for viral LRTI in children. This was already 
proposed by others, who saw a correlation with peak 
temperature, duration of fever and presence of pneu-
monia in mechanically ventilated patients.17 19 Although 
SAP levels significantly increase during infection, no 
correlation could be observed with disease severity in 
children with viral LRTI. Therefore, it appears that SAP 
could not be used as a biomarker for disease severity in 
viral or bacterial infections.28 This study is the first to 
describe the remarkable kinetics of CFP (properdin) 
levels, which decrease during severe viral infection in 
children. We were unable to find an explanation in 
the literature. However, since CFP levels restored in the 
available recovery samples, a deficiency is highly unlikely. 
Other possible explanations for the decrease might be 
consumption, as occurs with other complement factors, or 
an unrecognised bacterial coinfection. Although cultures 
were routinely taken at the intensive care unit before the 
start of selective digestive decontamination (SDD) antibi-
otics, bacterial infections cannot be ruled out completely. 
A subanalysis of patients with (n=10) and without (n=15) 
positive bacterial cultures on the ICU showed no differ-
ence in protein levels (data not shown). During the study 
period, SDD was standard practice in the ICU and, there-
fore, all severe patients would have had at least one gift 
of prophylactic antibiotics before the study samples were 
taken.
The prediction rule for the identification of children 
with a mild course of disease appeared to be insufficient 
for clinical use (AUC 0.65). However, the performance 
in children less than 2 months of age (AUC 0.88) is 
promising and might provide additive value in clinical 
decision-making. Currently, there are no comparable 
laboratory-based studies assessing the identification of 
mild disease. Clinical rules for safe discharge based on 
age and findings at physical examination have been devel-
oped. Unfortunately, in these studies, children below 2 
months of age were excluded or automatically admitted 
regardless of the necessity of treatment.5 33 37 38
The identification of patients with severe disease was 
accurate with the chosen inflammatory markers (AUC 
0.89). The prediction performed better than age on itself 
(AUC 0.77). A prediction rule based on interleukin-8 and 
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regulated on activation, normal T Cell expressed and 
secreted (RANTES) in plasma and CD4+ T cell counts 
accurately identifies severe disease but needs to be vali-
dated in an independent cohort to establish clinical 
potential.16 A combination of biochemical, haematolog-
ical and clinical data might further improve accuracy. A 
drawback of introducing clinical variables is that most 
of the published risk factors in clinical prediction are 
not objective or may change rapidly in time. Moreover, 
signs and symptoms of children can be ambiguous at the 
moment of presentation and only become clear after 
prolonged observation. Prediction rules using clinical 
data often show a lower AUC and validation studies of 
these rules are lacking or have a smaller sample size.4 39
Limitations of our study are the limited number of 
patients in the mild age group, especially patients younger 
than 2 months of age. This influenced our analyses and 
hindered the logistic regression analysis in the predic-
tion of mild disease. Since venapuncture is not always 
part of routine care, especially not in this patient group, 
parents often refuse participation or the venapuncture 
specific. Therefore, the performance of our rule in the 
mild patient group under 2 months of age needs further 
testing Moreover, a prospective study in which results are 
available for the clinicians is needed to assess the clinical 
implications of our rule.
Age is always a confounder in studies on disease severity 
in infants with RSV. We could not find correlations in the 
acute samples after correcting for age and multiple testing; 
however, we did observe a positive correlation between 
age and SAA and SAP in the recovery samples (data not 
shown). This is opposite to our findings during the acute 
phase of disease (higher levels in younger patients). 
Bruun et al studied plasma levels of CRP and SAA in chil-
dren and neonates, including preterms in healthy and 
diseased state. They demonstrated that with increasing 
age (preterm up to child), higher CRP and SAA levels 
are being produced during disease.40 Although when 
patients were healthy, the differences resolve. It is likely 
that the higher levels of SAA in our youngest (severely 
ill) patients is a result of disease severity. This shas already 
been demonstrated for bacterial infections.24 25 In our 
linear regression rule, SAA could be replaced with age of 
the patients which gave similar results.
It would be interesting to perform a study that assesses the 
plasma levels of our markers at different time points during 
viral infections to increase our insight in the kinetics. It is 
assumed that some biomarkers precede clinical symptoms 
and could therefore be used early in the course of disease 
to predict severe outcomes. The advantage of measuring 
markers in plasma is the possibility for easy implementa-
tion in current diagnostic laboratory settings, relative short 
time to measure, reproducibility of the assays and avail-
able options for standardisation. Moreover, with the use of 
tools for linear regression modelling, it is easy to add new 
markers to further optimise the predictive rule. In general, 
our results indicate that combining markers, in our case 
inflammatory proteins, could increase the performance of 
a test. This indicates that this method might also be useful 
in other settings. More specifically, due to the validation 
in an independent cohort, we can assume that our deci-
sion rule will perform as well in other hospital settings. 
Whether the combination of these plasma markers could 
also be used to predict severe bacterial infections need to 
be assessed in other studies.
Currently, there is no targeted therapy for most respira-
tory viruses and, therefore, there are no consequences to 
the early identification of patients with a severe course of 
disease besides optimisation of supportive care. The iden-
tification of children with a mild course of disease has 
more visible consequences, as can be measured in reduced 
hospitalisation rates or length of stay in the hospital. To 
truly estimate the value of the markers, a prospective study 
is needed. However, even before the markers are imple-
mented in the clinic, biomarkers could be used to stratify 
patients in clinical studies and as secondary end-point in 
intervention studies. With the current development of 
point-of-care tests, plasma protein levels can be available 
within a relevant time frame and could be beneficial for 
care in emergency rooms and by the general practitioner.
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